Literature DB >> 15691612

Arterial compliance changes in diabetic normotensive patients after angiotensin-converting enzyme inhibition therapy.

Athanasios J Manolis1, Stella Iraklianou, Andreas Pittaras, Michael Zaris, Konstantinos Tsioufis, George Psaltiras, Demetra Psomali, Stefanos Foussas, Irene Gavras, Haralambos Gavras.   

Abstract

BACKGROUND: Diabetes mellitus (DM) is known to cause increased arterial wall stiffness and increased cardiovascular risk, even in the absence of hypertension. This study was designed to investigate whether use of an angiotensin-converting enzyme (ACE) inhibitor may improve arterial stiffness in normotensive diabetics, using pulse wave velocity (PWV) as a surrogate marker.
METHODS: We studied 42 patients (26 with type 2 DM, aged 56.5 +/- 9 years, 16 with type 1 DM, aged 41.5 +/- 11 years) by measuring PWV at baseline (compared to 15 age- and gender-matched normal subjects) and after 6 months of treatment with perindopril (4 mg/d).
RESULTS: At baseline, PWV was significantly higher in DM patients versus controls (13.09 +/- 2.59 v 9.5 +/- 1.6 m/sec, respectively, P < .001). After 6 months, PWV decreased significantly to 11.68 +/- 3.08 m/sec (P < .003) for the whole DM group. However, the results were driven by the change in the younger type 1 DM (from 12.59 +/- 1.59 to 10.35 +/- 2.21 m/sec, P < .001), whereas in the type 2 DM it was insignificant (from 13.37 +/- 3.0 to 12.42 +/- 3.28 m/sec). Blood pressure and other hemodynamic and biochemical parameters remained unchanged.
CONCLUSIONS: The results demonstrate that ACE inhibition can improve arterial elasticity and hence risk of cardiovascular complications even in normotensive diabetics. This short treatment was effective only in younger patients with type 1 diabetes, suggesting that early initiation of therapy before the onset of advanced structural alterations is likely to be more cardioprotective.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15691612     DOI: 10.1016/j.amjhyper.2004.08.014

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  11 in total

1.  Association of total marine fatty acids, eicosapentaenoic and docosahexaenoic acids, with aortic stiffness in Koreans, whites, and Japanese Americans.

Authors:  Akira Sekikawa; Chol Shin; Kamal H Masaki; Emma J M Barinas-Mitchell; Nobutaka Hirooka; Bradley J Willcox; Jina Choo; Jessica White; Rhobert W Evans; Akira Fujiyoshi; Tomonori Okamura; Katsuyuki Miura; Matthew F Muldoon; Hirotsugu Ueshima; Lewis H Kuller; Kim Sutton-Tyrrell
Journal:  Am J Hypertens       Date:  2013-07-02       Impact factor: 2.689

2.  Effect of rosiglitazone and ramipril on macrovasculopathy in patients with type 2 diabetes: needs longer treatment and/or higher doses?

Authors:  Sayeeda Rahman; Aziz Al-Shafi Ismail; Shaiful Bhari Ismail; Nyi Nyi Naing; Abdul Rashid Abdul Rahman
Journal:  Clin Pharmacol       Date:  2010-04-20

3.  Effect of ACE-inhibition on coronary microvascular function and symptoms in normotensive women with microvascular angina: A randomized placebo-controlled trial.

Authors:  Marie Mide Michelsen; Anna Bay Rask; Elena Suhrs; Kristoffer Flintholm Raft; Nis Høst; Eva Prescott
Journal:  PLoS One       Date:  2018-06-08       Impact factor: 3.240

Review 4.  Cardiac Autonomic Neuropathy: A Progressive Consequence of Chronic Low-Grade Inflammation in Type 2 Diabetes and Related Metabolic Disorders.

Authors:  Nour-Mounira Z Bakkar; Haneen S Dwaib; Souha Fares; Ali H Eid; Yusra Al-Dhaheri; Ahmed F El-Yazbi
Journal:  Int J Mol Sci       Date:  2020-11-27       Impact factor: 5.923

5.  Effect of direct renin inhibition on renal hemodynamic function, arterial stiffness, and endothelial function in humans with uncomplicated type 1 diabetes: a pilot study.

Authors:  David Z I Cherney; Vesta Lai; James W Scholey; Judith A Miller; Bernard Zinman; Heather N Reich
Journal:  Diabetes Care       Date:  2009-11-04       Impact factor: 19.112

6.  Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: the EFFORT study.

Authors:  Alexandros Briasoulis; Raymond Oliva; Rigas Kalaitzidis; Colleen Flynn; Ivana Lazich; Carrie Schlaffer; George Bakris
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-04-30       Impact factor: 3.738

7.  Effect of rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed, untreated diabetes and IGT patients: 1-year randomised, double-blind, placebo-controlled study.

Authors:  Sayeeda Rahman; Aziz Al-Shafi Ismail; Shaiful Bhari Ismail; Nyi Nyi Naing; Abdul Rashid Abdul Rahman
Journal:  Eur J Clin Pharmacol       Date:  2007-06-13       Impact factor: 3.064

8.  The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.

Authors:  David Zi Cherney; Bruce A Perkins; Nima Soleymanlou; Ronnie Har; Nora Fagan; Odd Erik Johansen; Hans-Juergen Woerle; Maximilian von Eynatten; Uli C Broedl
Journal:  Cardiovasc Diabetol       Date:  2014-01-29       Impact factor: 9.951

9.  Different Contributions of Physical Activity on Arterial Stiffness between Diabetics and Non-Diabetics.

Authors:  Takeshi Iwasa; Eisuke Amiya; Jiro Ando; Masafumi Watanabe; Takahide Murasawa; Issei Komuro
Journal:  PLoS One       Date:  2016-08-10       Impact factor: 3.240

10.  Frequency of Gestational Diabetes Mellitus Reappearance or Absence during the Second Pregnancy of Women Treated at Mayo Clinic between 2013 and 2018.

Authors:  Elizabeth Ann L Enninga; Aoife M Egan; Layan Alrahmani; Alexey A Leontovich; Rodrigo Ruano; Michael P Sarras
Journal:  J Diabetes Res       Date:  2019-11-22       Impact factor: 4.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.